Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03595683 | Pembrolizumab and EDP1503 in Advanced Melanoma | terminated | Phase 2 | 8 | University of ChicagoOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05675709 | Enhancing Skin Cancer Early Detection and Treatment in Primary Care | completed | N/A | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT02307630 |
| PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study |
| active not recruiting |
| N/A |
| 7 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Dec 4, 2025 |
| clinicaltrials |
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05393713 | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study | terminated | Phase 1 | 3 | Mayo ClinicOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06194929 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma(DETERMINE) | recruiting | Phase 1 / Phase 2 | 33 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | recruiting | Phase 1 | 6 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT04570332 | BO-112 With Pembrolizumab in Unresectable Malignant Melanoma(SPOTLIGHT203) | completed | Phase 2 | 42 | Highlight TherapeuticsINDUSTRY | 2 | Nov 26, 2025 | clinicaltrials |
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies(LONGSAFE) | recruiting | N/A | 40 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07223411 | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | recruiting | — | 20 | John KirkwoodOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT02639026 | Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers | completed | Phase 1 | 53 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01334008 | Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma | completed | N/A | 40 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT02706353 | APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT05668585 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | completed | Phase 1 | 89 | C4 Therapeutics, Inc.INDUSTRY | 5 | Nov 21, 2025 | clinicaltrials |
| NCT02854124 | Tracing Dissemination of Melanoma Cells in Healthy Tissues(DISSEMELA) | completed | — | 226 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04196452 | A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) | active not recruiting | — | 10 | Bristol-Myers SquibbINDUSTRY | 0 | Nov 20, 2025 | clinicaltrials |
| NCT04705168 | Study of the Nevisense Device to Assess Atypical Skin Lesions | completed | — | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06472661 | FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma(Mel 70) | recruiting | Early Phase 1 | 11 | University of VirginiaOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT01558349 | Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques | completed | — | 73 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT07236528 | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07237100 | Mirdametinib in Patients With Advanced NF1-mutant Melanoma | recruiting | Phase 2 | 10 | Kevin Kim, MDOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05429138 | Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma(MELpreserv) | recruiting | — | 80 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | active not recruiting | — | 1,150 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | terminated | Phase 1 | 17 | Bolt Biotherapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06206707 | FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis(Immunobiome) | recruiting | N/A | 20 | University of AarhusOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT01473004 | SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver | completed | Phase 2 | 48 | Thomas Jefferson UniversityOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT07091695 | Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab | completed | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | recruiting | Phase 2 | 99 | Emory UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT02775643 | Molecular Analysis of Childhood and Adolescent Melanocytic Lesions | recruiting | — | 500 | St. Jude Children's Research HospitalOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT07148245 | Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma | recruiting | — | 300 | University of California, San FranciscoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT01223248 | Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | active not recruiting | Phase 3 | 220 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Nov 4, 2025 | clinicaltrials |
| NCT04513028 | Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma | recruiting | N/A | 30 | Kelly McMastersOTHER | 1 | Oct 30, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Dec 8, 2025source: clinicaltrials